|
|
News Breaks | | | | March 4, 2013 | | 08:02 EDT |  | TEVA | Teva announces publication of Milprosa Phase III trial results
Teva Pharmaceutical Industries announced the publication of results of the Phase III clinical trial of Milprosa vaginal ring in Fertility and Sterility. The study compared the efficacy and safety of once-weekly Milprosa to daily 8% progesterone vaginal gel for luteal phase support in in vitro fertilization and found that clinical pregnancy rates per retrieval at eight and 12 weeks were comparable between patient groups. Adverse event profiles were similar between the two treatment groups and consistent with known AEs associated with progesterone. “The study results demonstrate that Milprosa may be an effective and safe option for progesterone supplementation during the luteal phase among women undergoing IVF,” said Laurel Stadtmauer, M.D., Ph.D., professor of Obstetrics and Gynecology at Jones Institute for Reproductive Medicine at Eastern Virginia Medical School and study author. “Since normal luteal function may be compromised among women undergoing IVF, progesterone supplementation is essential and the more options patients have, the better. If approved, the once-weekly dosing of Milprosa may offer convenience for patients.” | |
|
News For TEVA From The Last 14 Days Check below for free stories on TEVA the last two weeks. |
|
|
| May 22, 2013 | | 16:23 EDT | | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
 Subscribe for More Information | | | May 20, 2013 | | 11:27 EDT | | TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information | | | May 13, 2013 | | 09:44 EDT |  | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information | | | 07:49 EDT |  | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. | |
|
|
|
|
|
|
